Clinical outcome in patients with paroxysmal or persistent atrial fibrillation receiving Bepridil

Circulation Journal

Volumn 75, Issue 6, 2011, Pages 1334-1342

  Shiga, Tsuyoshi ^a   Suzuki, Atsushi ^a   Naganuma, Miyoko ^a   Hosaka, Fumitaka ^a   Shoda, Morio ^a   Hagiwara, Nobuhisa ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Bepridil; Mortality; Pharmacokinetics; Torsade de pointes

Indexed keywords

AMIODARONE; BEPRIDIL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLEEDING; BRADYCARDIA; BRAIN INFARCTION; COHORT ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBOLISM; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART PAROXYSMAL ATRIUM FIBRILLATION; HEART PERSISTENT ATRIUM FIBRILLATION; HUMAN; LIVER DYSFUNCTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROTOXICITY; OUTCOME ASSESSMENT; QT PROLONGATION; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BEPRIDIL; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79957804631     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1084     Document Type: Article

References (37)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med 1995; 155: 469-473.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
3. Crijns HJGM, Van Den Berg MP, Van Gelder IC, Van Veldhuisen DJ. Management of atrial fibrillation in the setting of heart failure. Eur Heart J 1997; 18: C45-C49.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Heart Study. Stroke 1991; 22: 983-988.
5. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952.
6. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107: 2920-2925.
7. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: Implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36: 1303-1309.
8. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
9. Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol 2008; 127: 299-306.
10. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A Comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
11. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al; for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
12. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KI, et al; for the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-2677.
13. Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-248.
14. The AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1509-1513.
15. Gill A, Flaim SF, Damiano BP, Sit SP, Brannan MD. Pharmacology of bepridil. Am J Cardiol 1992; 69: 11D-16D.
16. Prystowsky EN. Effects of bepridil on cardiac electrophysiologic properties. Am J Cardiol 1992; 69: 63D-67D.
17. Yasuda M, Nakazato Y, Yamashita H, Kawano Y, Iida Y, Nakazato K, et al. The clinical usefulness of oral bepridil in the treatment of atrial flutter and fibrillation refractory to class I antiarrhythmic drugs. Jpn J Electrocardiol 2003; 23: 53-60 (in Japanese).
18. Otsuka T, Yamashita T, Sagara K, Iinuma H, Fu L. Efficacy and limitation of oral bepridil for atrial fibrillation refractory to class I antiarrhythmic drugs. Jpn J Electrocardiol 2004; 24: 428-433 (in Japanese).
19. Fujiki A, Sakamoto T, Iwamoto J, Nishida K, Nagasawa H, Mizumaki K, et al. Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation. Circ J 2006; 70: 1138-1141.
20. Miyaji K, Tada H, Fukushima Kusano K, Hashimoto T, Kaseno K, Hiramatsu S, et al. Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. Circ J 2007; 71: 1250-1257.
21. Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003; 92: 472-475.
22. Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48.
23. Imai S, Saito F, Takase H, Enomoto M, Aoyama H, Yamaji S, et al. Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. Circ J 2008; 72: 709-715.
24. Yamashita T, Ogawa S, Sato T, Aizawa Y, Atarashi H, Fujiki A, et al; for the J-BAF Investigators. Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: A multicenter, randomized, placebo-controlled, double-blind study (J-BAF Study). Circ J 2009; 73: 1020-1027.
25. Yasuda M, Nakazato Y, Sasaki A, Kawano Y, Nakazato K, Tokano T, et al. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 2006; 70: 662-666.
26. Benet LZ. Pharmacokinetics and metabolism of bepridil. Am J Cardiol 1985; 55: 8C-13C.
27. Hollingshead LM, Faulds D, Fitton A, Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris. Drugs 1992; 44: 835-857.
28. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.
29. Braunwald E. Unstable angina: A classification. Circulation 1989; 80: 410-414.
30. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
31. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149: 489-496.
32. Pappone C, Radinovic A, Manguso F, Vicedomini G, Ciconte G, Sacchi S, et al. Atrial fibrillation progression and management: A5-year prospective follow-up study. Heart Rhythm 2008; 5: 1501-1507.
33. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: A 30-year follow-up study. Circulation 2007; 115: 3050-3056.
34. Singh BN. Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States. Am J Cardiol 1992; 69: 68D-74D.
35. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest 2005; 115: 2025-2032.
36. Sugi K, Kusano A, Noro M, Numata A, Tezuka N, Nakae T, et al. Characteristics of pharmacokinetics of bepridil. Jpn J Electrocardiol 2007; 27: 30-35 (in Japanese).
37. Kurita T, Yasauda M, Nakazato Y, Takahashi N, Yamashita T, Yasuda S, et al. Proarrhythmia of bepridil. Jpn J Electrocardiol 2007; 27: 61-73 (in Japanese).